Recombinant E-WE Thrombin Expression in E. coli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing thrombin mutants for therapeutic use are costly and inefficient, relying on expensive animal cell cultures that require complex maintenance and are prone to contamination, while existing anticoagulant therapies risk causing hemorrhage.
Innovation Solution
Development of a bacteria-derived recombinant E-WE thrombin enzyme precursor, expressed in Escherichia coli, which is glycosylation-free and can be activated using ecarin, offering a safer and more potent anticoagulant with reduced procoagulant activity towards fibrinogen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombin mutants are produced using animal cell cultures, then therapeutic efficacy is improved, but production cost and complexity increase
Solution Approach 1:
The patent uses bacteria (E. coli) to produce a recombinant copy of the thrombin mutant protein based on the mammalian thrombin gene sequence. The bacterial system replicates the protein structure without requiring complex animal cell culture infrastructure, thereby reducing production complexity while maintaining therapeutic efficacy through proper protein folding and post-translational modifications
Solution Approach 2:
The invention replaces expensive, difficult-to-maintain animal cell cultures with inexpensive, rapidly-growing bacterial systems. E. coli can be cultured cheaply in simple media and grows rapidly, making the production process more economical and scalable without sacrificing the ability to produce therapeutically effective thrombin mutants
2Manufacturing precision
If animal cell cultures are used for thrombin production, then protein quality is improved, but risk of contamination increases
Solution Approach 1:
The patent creates a bacterial copy of the mammalian thrombin gene to produce the protein in E. coli. This approach maintains protein quality by preserving the amino acid sequence and functional structure while using a bacterial host that is less prone to contamination by mammalian pathogens and easier to maintain under sterile conditions
Solution Approach 2:
Bacterial cultures have shorter generation times and simpler nutritional requirements than animal cells, making them easier to produce, dispose of, and replace. This reduces the risk and impact of contamination events, as contaminated bacterial cultures can be quickly discarded and restarted without the complex recovery procedures needed for animal cell lines
3Reliability
If conventional anticoagulant therapies are used, then thrombotic protection is improved, but risk of hemorrhage increases
Solution Approach 1:
The patent produces thrombin mutants with altered local properties at specific amino acid positions (such as W215A/E217A mutations in the anion-binding exosite). These localized changes modify the protein's interaction specificity, enhancing anticoagulant activity through protein C activation while reducing non-specific procoagulant effects on fibrinogen, thereby improving the therapeutic index
Solution Approach 2:
The invention changes the biochemical parameters of thrombin by introducing point mutations that alter substrate specificity. The mutations modify the enzyme's kinetic properties and binding characteristics, shifting its functional profile from predominantly procoagulant to predominantly anticoagulant, thus providing thrombotic protection with reduced hemorrhage risk
4Ease of manufacture
If bacteria are used for thrombin expression, then production cost decreases, but glycosylation capability is lost
Solution Approach 1:
The patent uses bacteria to produce a recombinant copy of thrombin that lacks glycosylation but maintains the correct amino acid sequence and three-dimensional structure. For therapeutic applications where glycosylation is not critical, this approach provides a cost-effective production method that achieves sufficient protein quality without requiring complex eukaryotic expression systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The E-WE thrombin enzyme demonstrates enhanced antithrombotic activity and safety, reducing the risk of hemorrhage and production costs, with improved therapeutic efficacy and scalability compared to mammalian cell-expressed counterparts.
Implementation Method 1
The enzyme ecarin can be used to cleave prothrombin between residues Arg271 and Thr272
Data Source
AI summary
One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.